{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:09:12Z","timestamp":1772147352897,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"CONACYT SALUD","award":["[2015-1-261455]"],"award-info":[{"award-number":["[2015-1-261455]"]}]},{"name":"CONACYT FORDECYT-PRONACES","award":["[grant Ciencia de Frontera-2019-64382]"],"award-info":[{"award-number":["[grant Ciencia de Frontera-2019-64382]"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10072-025-08304-6","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T05:08:38Z","timestamp":1750309718000},"page":"5081-5091","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advanced clinical stage Parkinson\u2019s disease is linked to proinflammatory and regulatory blood cell populations"],"prefix":"10.1007","volume":"46","author":[{"given":"Eduardo","family":"Ichikawa-Escamilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Espinosa-C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaquelin","family":"Leyva-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana D.","family":"\u00c1lvarez-Luqu\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asiel","family":"Arce-Sillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-698X","authenticated-orcid":false,"given":"Laura","family":"Adalid-Peralta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"8304_CR1","first-page":"1","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J et al (2017) Parkinson disease Nat Rev Dis Primers 3:1\u201321","journal-title":"Parkinson disease Nat Rev Dis Primers"},{"key":"8304_CR2","doi-asserted-by":"crossref","unstructured":"Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H (2021)Trends G, in the Incidence, Prevalence, and Years Lived With Disability of Parkinson\u2019s Disease in 204 Countries, Territories From, et al (1990) to 2019. Front Public Health 9","DOI":"10.3389\/fpubh.2021.776847"},{"key":"8304_CR3","doi-asserted-by":"crossref","unstructured":"Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C (2024) The epidemiology of Parkinson\u2019s disease. The Lancet. Elsevier B.V. p. 283\u201392","DOI":"10.1016\/S0140-6736(23)01419-8"},{"key":"8304_CR4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-Sponsored Revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23:2129\u20132170","journal-title":"Mov Disord"},{"key":"8304_CR5","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Violante M, Cervantes-Arriaga A (2014) La escala unificada de la enfermedad de Parkinson modificada por la Sociedad de Trastornos del Movimiento (MDS-UPDRS): aplicacion clinica e investigacion. Arch Neurocien (Mex)","DOI":"10.31157\/an.v19i3.50"},{"key":"8304_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/ene.12349","volume":"21","author":"P Mart\u00ednez-Mart\u00edn","year":"2014","unstructured":"Mart\u00ednez-Mart\u00edn P, Rodr\u00edguez-Bl\u00e1zquez C, Forjaz MJ, \u00c1lvarez-S\u00e1nchez M, Arakaki T, Bergareche-Yarza A et al (2014) Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson\u2019s disease patients. Eur J Neurol 21:519\u2013524","journal-title":"Eur J Neurol"},{"key":"8304_CR7","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.parkreldis.2013.05.017","volume":"19","author":"C Rodriguez-Blazquez","year":"2013","unstructured":"Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A et al (2013) The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson\u2019s disease. Parkinsonism Relat Disord 19:889\u2013893","journal-title":"Parkinsonism Relat Disord"},{"key":"8304_CR8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C et al (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations. Mov Disord 19:1020\u20131028","journal-title":"Mov Disord"},{"key":"8304_CR9","doi-asserted-by":"crossref","unstructured":"Bou\u00e7a-Machado R, Fernandes A, Ranzato C, Beneby D, Nzwalo H, Ferreira JJ (2022) Measurement tools to assess activities of daily living in patients with Parkinson\u2019s disease: A systematic review. Front Neurosci. Frontiers Media S.A.","DOI":"10.3389\/fnins.2022.945398"},{"key":"8304_CR10","doi-asserted-by":"crossref","unstructured":"Beck AT, Steer RA, Brown GK (1996) Beck depression inventory","DOI":"10.1037\/t00742-000"},{"key":"8304_CR11","first-page":"426","volume-title":"Holroyd-Leduc J","author":"Z Goodarzi","year":"2016","unstructured":"Goodarzi Z, Mrklas KJ, Roberts DJ, Jette N, Pringsheim T (2016) Holroyd-Leduc J. Detecting depression in Parkinson disease, A systematic review and meta-analysis. Neurology. Lippincott Williams and Wilkins, pp 426\u2013437"},{"key":"8304_CR12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mdc3.13262","volume":"8","author":"P Bugalho","year":"2021","unstructured":"Bugalho P, Ladeira F, Barbosa R, Marto JP, Borbinha C, da Concei\u00e7\u00e3o L et al (2021) Progression in Parkinson\u2019s Disease: Variation in Motor and Non-motor Symptoms Severity and Predictors of Decline in Cognition, Motor Function, Disability, and Health-Related Quality of Life as Assessed by Two Different Methods. Mov Disord Clin Pract 8:885\u2013895","journal-title":"Mov Disord Clin Pract"},{"key":"8304_CR13","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/mds.22121","volume":"23","author":"EB Forsaa","year":"2008","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Herlofson K, Alves G (2008) Predictors and course of health-related quality of life in Parkinson\u2019s disease. Mov Disord 23:1420\u20131427","journal-title":"Mov Disord"},{"key":"8304_CR14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/ene.12950","volume":"23","author":"KM Prakash","year":"2016","unstructured":"Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK (2016) The impact of non-motor symptoms on the quality of life of Parkinson\u2019s disease patients: A longitudinal study. Eur J Neurol 23:854\u2013860","journal-title":"Eur J Neurol"},{"key":"8304_CR15","unstructured":"Kouli A, Torsney KM, Kuan WL (2018) Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB GJ editors., Brisbane (AU): Codon Publications, editors. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects [Internet]"},{"key":"8304_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD et al (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523:337\u2013341","journal-title":"Nature"},{"key":"8304_CR17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","volume":"21","author":"A Gerhard","year":"2006","unstructured":"Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A et al (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol Dis 21:404\u2013412","journal-title":"Neurobiol Dis"},{"key":"8304_CR18","doi-asserted-by":"crossref","unstructured":"Phane Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debr\u00e9 P, et al. (1999) FcRII\/CD23 Is Expressed in Parkinson\u2019s Disease and Induces, In Vitro, Production of Nitric Oxide and Tumor Necrosis Factor-in Glial Cells","DOI":"10.1523\/JNEUROSCI.19-09-03440.1999"},{"key":"8304_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/mds.26563","volume":"31","author":"CH Williams-Gray","year":"2016","unstructured":"Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR et al (2016) Serum immune markers and disease progression in an incident Parkinson\u2019s disease cohort (ICICLE-PD). Mov Disord 31:995\u20131003","journal-title":"Mov Disord"},{"key":"8304_CR20","doi-asserted-by":"crossref","unstructured":"Chen Z, Chen S, Liu J (2018) The role of T cells in the pathogenesis of Parkinson\u2019s disease. Prog Neurobiol. Elsevier Ltd. p. 1\u201323","DOI":"10.1016\/j.pneurobio.2018.08.002"},{"key":"8304_CR21","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Nogales C, Garbayo E, Carmona-Abell\u00e1n MM, Luquin MR, Blanco-Prieto MJ (2016) Brain aging and Parkinson\u2019s disease: New therapeutic approaches using drug delivery systems. Maturitas. Elsevier Ireland Ltd p. 25\u201331","DOI":"10.1016\/j.maturitas.2015.11.009"},{"key":"8304_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1096\/fj.04-2751com","volume":"19","author":"W Zhang","year":"2005","unstructured":"Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML et al (2005) Aggregated \u03b1-synuclein activates microglia: a process leading to disease progression in Parkinson\u2019s disease. FASEB J 19:533\u2013542","journal-title":"FASEB J"},{"key":"8304_CR23","doi-asserted-by":"crossref","unstructured":"Troncoso-Escudero P, Parra A, Nassif M, Vidal RL (2018) Outside in: Unraveling the role of neuroinflammation in the progression of Parkinson\u2019s disease. Front Neurol. Frontiers Media S.A.","DOI":"10.3389\/fneur.2018.00860"},{"key":"8304_CR24","doi-asserted-by":"crossref","unstructured":"von Bernhardi R, Eugen\u00edn-von Bernhardi L, Eugen\u00edn J (2015) Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci. Frontiers Media S.A.","DOI":"10.3389\/fnagi.2015.00124"},{"key":"8304_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.parkreldis.2005.07.005","volume":"11","author":"Y Baba","year":"2005","unstructured":"Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T (2005) Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 11:493\u2013498","journal-title":"Parkinsonism Relat Disord"},{"key":"8304_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2009.12.017","volume":"38","author":"M Calopa","year":"2010","unstructured":"Calopa M, Bas J, Call\u00e9n A, Mestre M (2010) Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol Dis 38:1\u20137","journal-title":"Neurobiol Dis"},{"key":"8304_CR27","doi-asserted-by":"crossref","unstructured":"Kustrimovic N, Comi C, Magistrelli L, Rasini E, Legnaro M, Bombelli R, et al. (2018) Parkinson\u2019s disease patients have a complex phenotypic and functional Th1 bias: Cross-sectional studies of CD4+ Th1\/Th2\/T17 and Treg in drug-na\u00efve and drug-treated patients. J Neuroinflammation 15","DOI":"10.1186\/s12974-018-1248-8"},{"key":"8304_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1600-0404.1994.tb02699.x","volume":"90","author":"U Fiszer","year":"1994","unstructured":"Fiszer U, Mix E, Fredrikson S, Kostulas V, Link H (1994) Parkinson\u2019s disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO\u2019- T cells in peripheral blood. Acta Neurol Scand 90:160\u2013166","journal-title":"Acta Neurol Scand"},{"key":"8304_CR29","doi-asserted-by":"crossref","unstructured":"Bas J, Calopa M, Mestre M, Mollev\u0131 DG, Cutillas B, Ambrosio S, et al. (2001) Lymphocyte populations in Parkinson\u2019s disease and in rat models of parkinsonism. J Neuroimmunol.","DOI":"10.1016\/S0165-5728(00)00422-7"},{"key":"8304_CR30","doi-asserted-by":"crossref","unstructured":"Hisanaga K, Asagi M, Itoyama Y, Iwasaki Y (2001) Increase in Peripheral CD4 Bright + CD8 Dull + T Cells in Parkinson Disease. Arch Neurol 58:1580.","DOI":"10.1001\/archneur.58.10.1580"},{"key":"8304_CR31","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Luqu\u00edn DD, Arce-Sillas A, Leyva-Hern\u00e1ndez J, Sevilla-Reyes E, Boll MC, Montes-Moratilla E, et al. (2019) Regulatory impairment in untreated Parkinson\u2019s disease is not restricted to Tregs: Other regulatory populations are also involved. J Neuroinflammation 16","DOI":"10.1186\/s12974-019-1606-1"},{"key":"8304_CR32","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11481-012-9402-z","volume":"7","author":"JAH Saunders","year":"2012","unstructured":"Saunders JAH, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto DR et al (2012) CD4+ regulatory and effector\/memory T cell subsets profile motor dysfunction in Parkinson\u2019s disease. J Neuroimmune Pharmacol 7:927\u2013938","journal-title":"J Neuroimmune Pharmacol"},{"key":"8304_CR33","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mds.22875","volume":"25","author":"YJ Zhao","year":"2010","unstructured":"Zhao YJ, Wee HL, Chan YH, Seah SH, Au WL, Lau PN et al (2010) Progression of Parkinson\u2019s disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord 25:710\u2013716","journal-title":"Mov Disord"},{"key":"8304_CR34","doi-asserted-by":"crossref","unstructured":"Thome AD, Atassi F, Wang J, Faridar A, Zhao W, Thonhoff JR, et al. (2021) Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson\u2019s disease. NPJ Parkinsons Dis 7","DOI":"10.1038\/s41531-021-00188-5"},{"key":"8304_CR35","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-024-02790-2","volume":"131","author":"A Arce-Sillas","year":"2024","unstructured":"Arce-Sillas A, \u00c1lvarez-Luqu\u00edn D, Leyva-Hern\u00e1ndez J, Montes-Moratilla E, Vivas-Almaz\u00e1n V, P\u00e9rez-Correa C et al (2024) Increased levels of regulatory T cells and IL-10-producing regulatory B cells are linked to improved clinical outcome in Parkinson\u2019s disease: a 1-year observational study. J Neural Transm (Vienna) 131:901\u2013916","journal-title":"J Neural Transm (Vienna)"},{"key":"8304_CR36","doi-asserted-by":"crossref","unstructured":"Garc\u00eda DS, Fonticoba T de D, Bartolom\u00e9 CC, R\u00edos LN, Roca LG, Mir\u00f3 CM, et al. (2021) Predictors of loss of functional independence in parkinson\u2019s disease: Results from the coppadis cohort at 2-year follow-up and comparison with a control group. Diagnostics 11","DOI":"10.3390\/diagnostics11101801"},{"key":"8304_CR37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jneuroim.2010.12.001","volume":"233","author":"MA Gruden","year":"2011","unstructured":"Gruden MA, Sewell RDE, Yanamandra K, Davidova TV, Kucheryanu VG, Bocharov EV et al (2011) Immunoprotection against toxic biomarkers is retained during Parkinson\u2019s disease progression. J Neuroimmunol 233:221\u2013227","journal-title":"J Neuroimmunol"},{"key":"8304_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jneuroim.2012.07.015","volume":"252","author":"CH Stevens","year":"2012","unstructured":"Stevens CH, Rowe D, Morel-Kopp MC, Orr C, Russell T, Ranola M et al (2012) Reduced T helper and B lymphocytes in Parkinson\u2019s disease. J Neuroimmunol 252:95\u201399","journal-title":"J Neuroimmunol"},{"key":"8304_CR39","doi-asserted-by":"crossref","unstructured":"Wang P, Luo M, Zhou W, Jin X, Xu Z, Yan S, et al. (2022) Global Characterization of Peripheral B Cells in Parkinson\u2019s Disease by Single-Cell RNA and BCR Sequencing. Front Immunol 13","DOI":"10.3389\/fimmu.2022.814239"},{"key":"8304_CR40","doi-asserted-by":"crossref","unstructured":"Seifert HA, Vandenbark AA, Offner H (2018) Regulatory B cells in experimental stroke. Immunology. Blackwell Publishing Ltd. p. 169\u201377","DOI":"10.1111\/imm.12887"},{"key":"8304_CR41","doi-asserted-by":"crossref","unstructured":"Vasileiadis GK, Dardiotis E, Mavropoulos A, Tsouris Z, Tsimourtou V, Bogdanos DP, et al. (2018) Regulatory B and T lymphocytes in multiple sclerosis: friends or foes? Autoimmunity Highlights. Springer-Verlag Italia s.r.l.","DOI":"10.1007\/s13317-018-0109-x"},{"key":"8304_CR42","doi-asserted-by":"publisher","unstructured":"Santos-Lobato BL, Gardinassi LG, Bortolanza M, Peti APF, Pimentel \u00c2 V, Faccioli LH, et al. (2022) Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson\u2019s Disease: Focus on Neuroinflammation. Mol Neurobiol 59:1140\u201350. https:\/\/doi.org\/10.1007\/s12035-021-02625-1","DOI":"10.1007\/s12035-021-02625-1"},{"key":"8304_CR43","doi-asserted-by":"publisher","unstructured":"Santos-Lobato BL, Bortolanza M, Pinheiro LC, Batalh\u00e3o ME, Pimentel \u00c2 V, Capellari-Carnio E, et al. (2022) Levodopa-induced dyskinesias in Parkinson\u2019s disease increase cerebrospinal fluid nitric oxide metabolites\u2019 levels. J Neural Transm 129:55\u201363. https:\/\/doi.org\/10.1007\/s00702-021-02447-4","DOI":"10.1007\/s00702-021-02447-4"},{"key":"8304_CR44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s12640-021-00345-x","volume":"39","author":"DP Ferrari","year":"2021","unstructured":"Ferrari DP, Bortolanza M, Del Bel EA (2021) Interferon-\u03b3 Involvement in the Neuroinflammation Associated with Parkinson\u2019s Disease and L-DOPA-Induced Dyskinesia. Neurotox Res 39:705\u2013719","journal-title":"Neurotox Res"},{"key":"8304_CR45","doi-asserted-by":"crossref","unstructured":"Carta AR, Mulas G, Bortolanza M, Duarte T, Pillai E, Fisone G et al. (2017) l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role? European Journal of Neuroscience. Blackwell Publishing Ltd. p. 73\u201391","DOI":"10.1111\/ejn.13482"},{"key":"8304_CR46","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/mds.27815","volume":"34","author":"SK Nissen","year":"2019","unstructured":"Nissen SK, Shrivastava K, Schulte C, Otzen DE, Goldeck D, Berg D et al (2019) Alterations in Blood Monocyte Functions in Parkinson\u2019s Disease. Mov Disord 34:1711\u20131721","journal-title":"Mov Disord"},{"key":"8304_CR47","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V (2022) Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol 22:657\u2013673","journal-title":"Nat Rev Immunol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08304-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08304-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08304-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T03:13:01Z","timestamp":1759288381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08304-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["8304"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08304-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with all regulations for research involving human subjects established by Mexican law and international regulations (Declaration of Helsinki). The Ethics Committee of the Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda, M\u00e9xico, approved this protocol with permit number 145\/19, certifying that it was conducted in strict compliance with ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All subjects included signed an informed consent form before enter the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}